Prognostic value of Neutrophil-to-Lymphocyte Ratio (NLR) in patients with Leptomeningeal Metastasis (LM) from solid tumors
Open Access
- 21 April 2026
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 26 (1)
Abstract
Leptomeningeal metastasis (LM) arising from solid tumors signifies a late-stage complication in the cancer trajectory, often portending a poor prognosis. The prognostic factors remain elusive. Prior research has established the Neutrophil-to-Lymphocyte Ratio (NLR) as an independent prognostic marker in various malignancies; however, its prognostic utility in LM patients remains underexplored. This study aims to investigate the prognostic significance of NLR at the time of LM diagnosis. We conducted a retrospective analysis involving 490 diagnosed LM patients with solid tumor origins at Zhejiang Cancer Hospital. NLR was computed at the time of LM diagnosis. Kaplan-Meier curves and Cox proportional models were employed to examine the association between NLR and overall survival (OS). Following exclusions, the cohort comprised 384 patients. The median age was 55 years (interquartile range, IQR: 51-61.25), with a median OS was 6.45 months (IQR: 2.1–15.6) and a median NLR was 4.09 (IQR: 2.81–7.57). The median interval between LM diagnosis and NLR assessment was 1 day (IQR: 0–3). NLR proved effective in stratifying the prognosis of LM patients (HR = 1.02, 95% CI 1.01–1.04, p = 0.009). Stratifying patients based on the median NLR into low- and high-risk groups revealed that the high-risk group exhibited a 1.324-fold increased risk of death compared to the low-risk group (HR = 1.324, 95% CI 1.069–1.640, p = 0.010). Subgroup analysis indicated that NLR independently predicted prognosis specifically in the invasive breast cancer subgroup (p = 0.002). NLR emerges as a simple and accessible prognostic indicator in newly diagnosed patients with leptomeningeal metastasis stemming from solid tumors. The online version contains supplementary material available at 10.1186/s12885-026-16043-w. The online version contains supplementary material available at 10.1186/s12885-026-16043-w.Keywords
Funding Information
- Zhejiang Provincial National Science Foundation (LY21H160007)
This publication has 45 references indexed in Scilit:
- Lipid-associated macrophages for osimertinib resistance and leptomeningeal metastases in NSCLCCell Reports, 2024
- The temporal progression of lung immune remodeling during breast cancer metastasisCancer Cell, 2024
- Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upESMO Open, 2023
- Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal MetastasisClinical Breast Cancer, 2017
- Breast cancer and leptomeningeal disease (LMD): hormone receptor status influences time to development of LMD and survival from LMD diagnosisJournal of Neuro-Oncology, 2013
- A retrospective case series of 103 consecutive patients with leptomeningeal metastasis and breast cancerJournal of Neuro-Oncology, 2013
- Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestationsBreast Cancer Research and Treatment, 2011
- Meningeal carcinomatosis in breast cancer: prognostic factors and outcomeJournal of Neuro-Oncology, 2011
- Breast cancer leptomeningeal metastasis—the role of multimodality treatmentJournal of Neuro-Oncology, 2007
- Leptomeningeal carcinomatosis: How does cancer reach the pia-arachnoid?Cancer, 1983